BioSpace News Archive

Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination.

Johnson & Johnson today announced that TREMFYA® (guselkumab) demonstrated rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement in scalp itch, as well as patient-reported health-related quality of life outcomes, including post-inflammatory pigmentation at 16 weeks.

Spruce Biosciences, Inc. today announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH).

Haystack Oncology, a Quest Diagnostics company and developer of best-in-class personalized MRD technology, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus’ SD-101, an investigational class C toll-like receptor-9 agonist.

ORIC Pharmaceuticals, Inc. today announced that it has agreed to sell approximately 12.5 million shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $10.00, representing a premium of approximately 10% to ORIC’s 5-day trailing average price.

RespireRx Pharmaceuticals Inc. is pleased to announce the appointment of Dr. Dariusz Nasiek MD, MBA to its board of directors.

MitoSense Inc. announces the successful closure of its Series Seed Funding Round led by Caydan Capital Partners, raising close to $3.5 million.

Single Pass, a leading provider of innovative medical devices, is pleased to announce an exclusive distribution agreement with Mermaid Medical Group, a renowned global medical technology company.

Tris Pharma, Inc. today announced the appointment of Franchesca Fowler, JD, as chief compliance officer and vice president, general counsel.

Virios Therapeutics, Inc. today announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”).